StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Earnings

Nektar Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$9.40M
-20.3% on a year earlier
Adjusted EPS, Q3 FY2026
-$1.63
-$1.85 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Nektar Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close$9.40M-20.3%-$1.63–Release
Q2 FY2026ended Jun 30, 2026Aug 13, 2026after the close$10.10M-9.8%-$1.23–Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026after the close$21.80M-25.3%-$1.78–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$11.80M-51.0%-$1.87-$1.85Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$11.20M-52.3%-$2.95-$2.78Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$10.50M-51.4%-$0.24-$0.22Release
Q4 FY2024ended Dec 31, 2024Mar 12, 2025after the close$29.20M+22.2%$0.03-$0.15Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$24.10M0.0%-$0.18–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$23.50M+14.6%-$0.25-$0.19Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$21.60M0.0%-$0.19–Release
Q4 FY2023ended Dec 31, 2023Mar 4, 2024after the close$23.90M+8.6%-$0.22–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Nektar Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Nektar Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Nektar Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Results
  6. News
  7. Update
  8. Update
  9. Results
  10. News
  11. Update
  12. Update
  13. Update
  14. Update
  15. Update

See a number that looks wrong?